Achieving Targeted Treatment Outcomes in IBD : Episode 8

Opinion

Video

August 6, 2024

Combination Therapy in Inflammatory Bowel Disease

Author(s):

Silvio Danese, MD, PhD ,Bruce Sands, MD

Medical experts in inflammatory bowel disease discuss the current evidence on dual advanced therapy for ulcerative colitis and Crohn's disease, highlighting the potential benefits, while also addressing the challenges and complexity of treatment management.

EP: 1.Treat-to-target in Inflammatory Bowel Disease

EP: 2.Recommended Targets When Treating Ulcerative Colitis/Crohn’s Disease in Clinic

EP: 3.Transmural Healing and Monitoring in Ulcerative Colitis and Crohn’s Disease

EP: 4.Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease

EP: 5.Suboptimal Treatment of Inflammatory Bowel Disease in Clinical Practice

EP: 6.Unmet Needs and Starting Advanced Treatment in Inflammatory Bowel Disease

EP: 7.Considerations for Choosing Advanced Treatments and Setting Patient Expectations

EP: 8.Combination Therapy in Inflammatory Bowel Disease

EP: 9.Measuring Patient Satisfaction with Inflammatory Bowel Disease Treatments and Communication Regarding Treatment Changes

What is the current evidence on Advanced Combination Therapy for UC and CD? What are the benefits and challenges of this approach?

Related Videos

Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD

Aflibercept 8 mg Shows Durability at 3 Years in Wet AMD with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center

Investigating Brensocatib, Potential First Treatment for Bronchiectasis, with James Chalmers, MBChB, PhD

Aflibercept 8 mg Noninferior for RVO in QUASAR with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center

AI in Dermatology: Emerging Insights and Diverging Perspectives

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.